Become Affiliate

PepFlow

Download

The Hunger Pulse

GHRP-6

An early synthetic growth hormone-releasing hexapeptide known for GH release, ghrelin-like appetite stimulation, and endocrine-response research.

GH pulseBody compositionRecovery
TierC
EvidencePreliminary
SafetyModerate Data
FDA statusNot Approved
Last reviewed October 25, 2026 52 citations How to read these labels

What is GHRP-6?

GHRP-6 is a synthetic growth hormone-releasing peptide that acts as a ghrelin/GHS receptor agonist. It stimulates pituitary GH release and is part of the older GHRP family that includes GHRP-6, GHRP-2, hexarelin, and ipamorelin.[17][15][34]

GHRP-6 is distinguished by pronounced appetite stimulation and more ACTH/cortisol/prolactin activity than cleaner GH secretagogues.[15][16]

GHRP-6 is one of the older growth hormone-releasing hexapeptides. The “6” refers to its hexapeptide structure, not a sixth-generation product, and it should be distinguished from GHRP-2, hexarelin, ipamorelin, and GHRH fragments.[34][17] For more context, read the GHRP-6 side-effect discussion.

What GHRP-6 is investigated for

GHRP-6 evidence is grouped by practical use case and injectable, topical, transdermal, and sublingual route context. Each use case separates confidence, human evidence, animal or mechanistic support, and the practical takeaway.

GH release and IGF-1 response

Injectable

56%Emerging

GHRP-6 is best framed as a GH secretagogue with limited long-term outcome evidence.[17][15][16][20][21][22]

Human evidence

Human studies support acute GH, ACTH, cortisol, and pharmacokinetic responses, but long-term fat-loss, lean-mass, cachexia, or wellness outcomes are not established.[17][15][16]

Animal / mechanistic evidence

Ghrelin/GHS receptor biology supports pituitary GH release and related endocrine effects.[17][15][16]

Appetite stimulation

Injectable

48%Preliminary

Appetite stimulation can be useful in wasting contexts or undesirable for fat-loss goals, so it should be presented as a goal-dependent effect.[15][16]

Human evidence

Human endocrine studies support GHRP-6 as a ghrelin-receptor secretagogue, but controlled human appetite-endpoint evidence remains limited.[15][16]

Animal / mechanistic evidence

Ghrelin-receptor biology directly supports appetite signaling and makes appetite stimulation a plausible GHRP-6 effect.[15][16]

Gastric motility

Injectable

30%Limited

Gastric-motility positioning is model-supported and should not be treated as a validated GI therapy.[45][47]

Human evidence

No controlled human trial establishes GHRP-6 as a treatment for gastroparesis, ileus, or delayed gastric emptying.[45][46]

Animal / mechanistic evidence

Mouse and rat studies report prokinetic gastric-emptying and intestinal-transit effects through ghrelin-receptor pathways.[45][46][47]

Fat loss, lean mass, and recovery

Injectable

28%Limited

Fat-loss, lean-mass, and recovery claims remain extrapolated from GH-axis pharmacology and preclinical injury models.[17][20]

Human evidence

Human GH-release and pharmacokinetic studies do not establish durable fat-mass, lean-mass, recovery, or cachexia outcomes.[17][15][16]

Animal / mechanistic evidence

Preclinical studies support tissue-injury, cardiac, lung, kidney, and skeletal-muscle hypotheses, but these remain model-based.[20][21][22][23]

Evidence snapshot

54%

Human evidence

Emerging

Available human studies support acute GH, ACTH, cortisol, and pharmacokinetic responses. Long-term body-composition, cachexia, and wellness outcomes are not established.[17][15][16]

46%

Animal / preclinical

Preliminary

Preclinical studies support tissue-injury, cardiac, lung, kidney, and skeletal-muscle hypotheses. These remain model-based signals, not validated treatment outcomes.[20][21][22]

65%

Mechanism support

Moderate

Ghrelin/GHS receptor activation directly explains GH release, appetite effects, and off-target endocrine monitoring. Mechanistic confidence is stronger than outcome confidence.[15][16]

Forms & administration

GHRP-6 has injectable, oral, nasal and sublingual research presentations, with limited human support for sublingual delivery. Topical wound gels and assisted skin-delivery formulations remain experimental, with laboratory or animal evidence. Amounts and preparation are route-specific.[17][15][16][41][42][43]

InjectableTopicalTransdermalSublingual

Dosing & protocols

These ranges are general reference points, not personal dosing instructions.

Typical Range

Injectable protocols use 100-300 mcg per dose. Intranasal protocols use 0.03 mg/kg; oral protocols use 0.3 mg/kg.[17][15][16][43][44]

Frequency

Injections use 2-3 doses daily. Intranasal use is a single dose; oral protocols use 2 doses daily.[17][15][16][43][44]

Timing Considerations

Common timing is morning, before a workout, or before bed. Pre-meal dosing is used for appetite support.[17][15][16][43][44]

What to expect

First week

Injectable GH-pulse use may first show stronger hunger, sleep changes, water retention, or shifts in training-day recovery.[15][16]

Weeks 4-8

Appetite pattern, waist, training tolerance, recovery notes, IGF-1, and fasting glucose become clearer once timing and food windows are consistent.[17][15][16]

After stopping

Appetite, water retention, and IGF-1-related markers often drift toward baseline after short-acting GH secretagogue exposure ends.[17][15][34]

Safety profile

Injectable GHRP-6 safety centers on hunger, water retention, glucose and IGF-1 effects, ACTH/cortisol/prolactin biology, injection quality, pregnancy avoidance, active malignancy caution, and sports prohibition.[17][15][16][36][38]

Common side effects

Cautions

Who GHRP-6 is not for

Route-specific avoid and medical-review notes:

  • Active or recent cancer

    Avoid outside specialist-directed care because GH/IGF-1 pathway stimulation can be inappropriate in malignancy contexts.[17][15][16][36][38]

  • Pregnancy or breastfeeding

    Avoid because reproductive and lactation safety are not established for unapproved GH secretagogue use.[17][15][16][36][38]

  • Acromegaly or GH excess

    Do not add GH secretagogue stimulation when GH/IGF-1 excess is present or suspected.[17][15][16][36][38]

Drug & supplement interactions

Documented interactions are separated from theoretical or route-specific cautions.

Theoretical interactions

  • Diabetes medications

    Diabetes medications can become harder to adjust when injectable GH-axis stimulation shifts glucose control; this is a theoretical GH/insulin-axis caution.[17][15][16][36][38]

  • Other GH-axis agents

    GHRH analogs, GHRPs, or HGH can add overlapping IGF-1, water-retention, glucose, and sports-risk concerns with injectable GHRP-6; this is a stack-level safety caution.[17][15][16][36][38]

Pairing notes

Not recommended with

Somatropin: compounded GH/IGF-1 effectsInjectable

This pairing compounds GH/IGF-1 stimulation through direct growth hormone plus an upstream release signal, increasing the need to review IGF-1, glucose, fluid retention, joint symptoms, and the reason for using both.[44][38][48]

Ipamorelin: duplicate GH-release signalInjectable, Intranasal

Ipamorelin and GHRP-6 both stimulate the ghrelin/GHS receptor pathway to release growth hormone. Combining two secretagogues duplicates the same release signal without an established additive clinical benefit.[49][44][50][38]

GHRP-2: duplicate GH-release signalInjectable, Intranasal

GHRP-2 and GHRP-6 both stimulate the ghrelin/GHS receptor pathway to release growth hormone. Combining two secretagogues duplicates the same release signal without an established additive clinical benefit.[51][44][38]

Hexarelin: duplicate GH-release signalInjectable, Intranasal

GHRP-6 and Hexarelin both stimulate the ghrelin/GHS receptor pathway to release growth hormone. Combining two secretagogues duplicates the same release signal without an established additive clinical benefit.[44][52][38]

Related peptides

How it works

GHRP-6 is an older ghrelin/GHS receptor agonist that can stimulate pituitary GH release after injection. Human pharmacokinetic and endocrine studies also connect it with ACTH and cortisol responses, which is why it is not just a clean GH pulse in practical interpretation.[17][15]

The mechanism helps explain appetite and metabolic-monitoring concerns. Downstream GH and IGF-1 signaling can interact with glucose and fluid retention, while ghrelin-receptor activity can affect hunger; none of that establishes durable body-composition, recovery, sleep, or longevity benefit in people.[17][15][16]

Research gaps & open questions

What the current literature has not yet settled about GHRP-6:

01

Long-term controlled studies need to show whether GHRP-6 improves fat loss, lean mass, recovery, or sleep, and how repeated use affects blood sugar, IGF-1, cortisol, and prolactin.[17][15][16]

02

Direct comparisons with other growth-hormone-releasing peptides should measure real benefits and side effects, not only the size of a temporary growth-hormone pulse.[15][16]

03

Athletes need clearer data on detection windows and product-contamination risk because GHRP-6 is prohibited in sport.[40]

Common questions

Is GHRP-6 FDA-approved?

No. GHRP-6 has no FDA-approved injectable U.S. use, and it is not on the 503A Bulks List.[36][38]

Is GHRP-6 banned in tested sports?

Yes. WADA treats GHRPs and GH secretagogues such as GHRP-6 as S2-prohibited without a valid TUE.[40]

What makes GHRP-6 different?

GHRP-6 stands out for appetite stimulation plus more ACTH, cortisol, and prolactin activity than cleaner GH-secretagogue profiles.[15][16]

Myths & misconceptions

Myth

GHRP-6 is undetectable because it clears quickly.

Reality

Short plasma exposure does not mean no sports-detection risk; WADA class rules and urine metabolite methods matter.[40]

Myth

GHRP-6 is safe because it stimulates natural GH.

Reality

Stimulating endogenous GH is still pharmacologic and can affect appetite, glucose, water retention, IGF-1, cortisol, or prolactin depending on the compound.[17][15][16]

History & discovery

GHRP-6 is one of the older synthetic GH-releasing peptides, important because it helped define how ghrelin/GHS-receptor agonists amplify pituitary GH pulses and appetite-linked endocrine signaling.[17][15][34]

Early work showed maximal GH stimulation depended on endogenous GHRH, helping place GHRP-6 in the secretagogue pathway rather than direct hormone replacement.[34]

Volunteer and disease-context studies measured pharmacokinetics, GH, ACTH, and cortisol responses, giving GHRP-6 more human pharmacology than many research peptides.[17][15][16]

Anti-doping rules later made GHRP-6 a prohibited GH secretagogue, while U.S. regulatory materials kept it outside approved injectable-drug status.[40][36][38]

Published research52 citations

Show citationsHide citations

PepFlow library coverage

Keep It Organized

Stay on track with your long-term goals.

Use PepFlow to record your GHRP-6 protocol, set reminders for your own schedule, and review your history.

Download on the App StoreGet it on Google Play
PepFlow calendar on Thursday, April 9, listing BPC-157 at 10:00 and GHK-CU at 18:00